LB-100 by Lixte Biotechnology for Synovial Sarcoma: Likelihood of Approval

Retrieved on: 2024-01-22 17:07:47

Tags for this article:

Click the tags to see associated articles and topics

LB-100 by Lixte Biotechnology for Synovial Sarcoma: Likelihood of Approval. View article details on hiswai:

Excerpt

LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Synovial Sarcoma.

Article found on: www.pharmaceutical-technology.com